Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612451 | 1.00 | NR3C1 (0.39) | NR3C1CHRM4PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL22612387 | 0.85 | LIPE (0.49) | LIPE | |
| SCHEMBL22612385 | 0.85 | LIPE (0.49) | LIPE | |
| SCHEMBL22612365 | 0.81 | GRM5 (0.36) | SCN9A | |
| SCHEMBL22612362 | 0.81 | GRM5 (0.36) | SCN9A | |
| SCHEMBL22612391 | 0.79 | KMT2A (0.40) | LIPESCN9A | |
| SCHEMBL22612392 | 0.79 | KMT2A (0.40) | LIPESCN9A | |
| SCHEMBL22612429 | 0.78 | AR (0.42) | — | |
| SCHEMBL22612431 | 0.78 | AR (0.42) | — | |
| SCHEMBL22612355 | 0.73 | GRM5 (0.37) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218851-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, IRF3 | NR3C1 7/4885CHRM4 4203/4885PRKAA2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.